Evaluation of the efficacy, prognosis and safety of dexamethasone in the treatment of different types of non-puerperal mastitis: A retrospective study.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Dexamethasone*/therapeutic use ; Dexamethasone*/adverse effects ; Mastitis*/drug therapy; Humans ; Female ; Retrospective Studies ; Adult ; Middle Aged ; Prognosis ; Treatment Outcome

Competing Interests: The authors have declared that no competing interests exist.
Objective: To analyze the efficacy and safety of dexamethasone in the treatment of non-puerperal mastitis (NPM), providing a new idea for the treatment of NPM.
Methods: From August 1, 2017 to August 30, 2024, case data were collected from 552 patients with NPM. After grouping according to different treatment options, the SPSS statistical software was used for retrospective analysis of the collected data.
Results: The number of days of drug treatment before operation in group B was less than other groups (p < 0.001). The group B had the most significant relief of pain symptoms and shorter time to complete relief of pain than other groups (p < 0.001). There were statistically significant differences between the 5 groups in the time required for pain to disappear and the time required for the volume to be reduced by half after treatment (p < 0.05).The overall efficacy evaluation had the highest effective rate in Group B (100%) and the lowest in Group D (2.10%), and the difference was statistically significant (p < 0.001).No side effects such as abnormalities in liver and kidney functions, water-electrolyte disorders, or peptic ulcers were observed in the five groups during drug treatment. There was no statistically significant difference in the occurrence of side effects such as rash, diarrhoea and hyperglycaemia among patients in the five groups (p > 0.05).The side effects of nausea (vomiting) and skin pigmentation in group E were higher than other groups(p < 0.001). In terms of weight gain (full moon face), nervous excitability (insomnia) and menstrual disorders, group B was lower than other groups (except group D without hormone therapy)(p < 0.001). In terms of postoperative recurrence after ipsilateral breast surgery, the recurrence rates of patients in group B were lower than those of the other four groups, and group D had the highest recurrence rate (8.30%), with a statistically significant difference (p < 0.001). Satisfaction survey found that group B had the highest satisfaction rate other groups (p < 0.05). The number of days required for the volume to be reduced by half after treatment was the most influential factor in the satisfaction survey. At the same time, we found that the obvious effect and recovery rate of GLM group was higher than that of PCM group, and the difference was statistically significant (p < 0.05).
Conclusion: Dexamethasone combined with levofloxacin/Metronidazole in the treatment of NPM has many advantages: first of all, it can significantly relieve the pain symptoms caused by the disease and effectively reduce the size of the lesion. Meanwhile, for the patients who plan to undergo surgery, the number of days of preoperative drug treatment can be reduced, and the overall effective rate is the highest. Secondly, the short-term application of drugs to treat side effects less, high safety; in the meantime, the risk of recurrence of the ipsilateral breast was less and the satisfaction of the patients was higher. The overall significant efficiency and recovery rate of GLM patients were higher than those of PCM patients.
(Copyright: © 2025 Wang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

Pathology. 2018 Dec;50(7):742-747. (PMID: 30389215)
Chin Med J (Engl). 2021 May 19;134(15):1765-1767. (PMID: 34039865)
Radiographics. 2018 Mar-Apr;38(2):330-356. (PMID: 29528819)
Inflammation. 2022 Apr;45(2):739-752. (PMID: 34997873)
Mediators Inflamm. 2017;2017:5309081. (PMID: 28182101)
Ann Med Surg (Lond). 2021 Jan 18;62:140-144. (PMID: 33520211)
Mil Med Res. 2022 Apr 26;9(1):20. (PMID: 35473758)
Eur Radiol. 2018 Mar;28(3):992-999. (PMID: 28956122)
J Invest Surg. 2022 Mar;35(3):709-720. (PMID: 33691563)
J Clin Med. 2020 Mar 30;9(4):. (PMID: 32235676)
Gland Surg. 2020 Aug;9(4):936-949. (PMID: 32953603)
J Inflamm Res. 2023 Sep 28;16:4347-4361. (PMID: 37791120)
Ann Diagn Pathol. 2021 Dec;55:151812. (PMID: 34500135)
Pharmacol Rep. 2022 Feb;74(1):229-240. (PMID: 34837648)
Int J Biol Sci. 2021 Apr 10;17(6):1530-1537. (PMID: 33907516)
Oncol Lett. 2020 Jan;19(1):840-848. (PMID: 31885718)
J Infect. 2023 Dec;87(6):490-497. (PMID: 37757919)
Breast J. 2019 Jul;25(4):790-791. (PMID: 31111604)
Ann Acad Med Singap. 2021 Aug;50(8):598-605. (PMID: 34472554)
Rheumatol Int. 2021 Jun;41(6):1175-1181. (PMID: 33649961)
Korean J Radiol. 2018 Jan-Feb;19(1):5-14. (PMID: 29353994)
Nutrients. 2022 Nov 14;14(22):. (PMID: 36432503)
Breast Care (Basel). 2022 Apr;17(2):172-179. (PMID: 35707181)
Asian J Surg. 2023 Feb;46(2):1153-1154. (PMID: 36050239)
ACS Biomater Sci Eng. 2022 May 9;8(5):1763-1790. (PMID: 35439408)
Int J Womens Health. 2024 Dec 06;16:2113-2122. (PMID: 39659296)

7S5I7G3JQL (Dexamethasone)

Date Created: 20250611 Date Completed: 20250611 Latest Revision: 20250614

20250614

PMC12157058

10.1371/journal.pone.0325739

40498798